ArticleThe American journal of pathology2015
Myofibroblastic Conversion and Regeneration of Mesothelial Cells in Peritoneal and Liver Fibrosis.
Article in The American journal of pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Mechanisms of Peritoneal Fibrosis: Focus on Immune Cells-Peritoneal Stroma Interactions.Frontiers in immunology · 2021Pooled it
- Mesothelial Cells in Fibrosis: Focus on Intercellular Crosstalk.Biomolecules · 2026Review
- Role of progesterone action in inguinal hernia formation via skeletal muscle fibrosis and atrophy.JCI insight · 2025Article
- Dynamic WT1 expression during gastrulation specifies peritoneal smooth muscle fate independently of mesothelial fate.Development (Cambridge, England) · 2025Article
- Biodegradable exosome-engineered hydrogels for the prevention of peritoneal adhesions via anti-oxidation and anti-inflammation.Materials today. Bio · 2024Article
- Vascular disease persistence in giant cell arteritis: are stromal cells neglected?Annals of the rheumatic diseases · 2024Review
- Low- and High-Grade Glioma-Associated Vascular Cells Differentially Regulate Tumor Growth.Molecular cancer research : MCR · 2024Article
- Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis?International journal of molecular sciences · 2024Review
- Fibroblasts in liver cancer: functions and therapeutic translation.The lancet. Gastroenterology & hepatology · 2023Review
- p53 and Myofibroblast Apoptosis in Organ Fibrosis.International journal of molecular sciences · 2023Review
- Activated protein C inhibits mesothelial-to-mesenchymal transition in experimental peritoneal fibrosis.Journal of thrombosis and haemostasis : JTH · 2023Article
- Restoration of WT1/miR-769-5p axis by HDAC1 inhibition promotes MMT reversal in mesenchymal-like mesothelial cells.Cell death & disease · 2022Article
- Molecular and Cellular Markers in Chlorhexidine-Induced Peritoneal Fibrosis in Mice.Biomedicines · 2022Article
- Mechanisms of Peritoneal Mesothelial Cells in Peritoneal Adhesion.Biomolecules · 2022Review
- Suspension culture promotes serosal mesothelial development in human intestinal organoids.Cell reports · 2022Article
- Article
- Restricted differentiative capacity of Wt1-expressing peritoneal mesothelium in postnatal and adult mice.Scientific reports · 2021Article
- Using Zebrafish as a Disease Model to Study Fibrotic Disease.International journal of molecular sciences · 2021Review
- Post-Surgical Peritoneal Scarring and Key Molecular Mechanisms.Biomolecules · 2021Review
- Cell barrier function of resident peritoneal macrophages in post-operative adhesions.Nature communications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Mesothelial cells (MCs) form a single epithelial layer and line the surface of body cavities and internal organs. Patients who undergo peritoneal dialysis often develop peritoneal fibrosis that is characterized by the accumulation of myofibroblasts in connective tissue. Although MCs are believed to be the source of myofibroblasts, their contribution has remained obscure. We determined the contribution of peritoneal MCs to myofibroblasts in chlorhexidine gluconate (CG)-induced fibrosis compared with that of phenotypic changes of liver MCs. CG injections resulted in disappearance of MCs from the body wall and the accumulation of myofibroblasts in the connective tissue. Conditional linage tracing with Wilms tumor 1 (Wt1)-CreERT2 and Rosa26 reporter mice found that 17% of myofibroblasts were derived from MCs in peritoneal fibrosis. Conditional deletion of transforming growth factor-β type II receptor in Wt1(+) MCs substantially reduced peritoneal fibrosis. The CG treatment also induced myofibroblastic conversion of MCs in the liver. Lineage tracing with Mesp1-Cre mice revealed that Mesp1(+) mesoderm gave rise to liver MCs but not peritoneal MCs. During recovery from peritoneal fibrosis, peritoneal MCs, but not liver MCs, contribute to the regeneration of the peritoneal mesothelium, indicating an inherent difference between parietal and visceral MCs. In conclusion, MCs partially contribute to myofibroblasts in peritoneal and liver fibrosis, and protection of the MC layer leads to reduced development of fibrous tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.